This presentation by Izukanji Sikazwe, Head of HIV at The Global Fund, during AIDS 2026 explores how the field might harness artificial intelligence in response to HIV. Izukanji Sikazwe unpacks what AI must be, what we must build, and the promise of AI in HIV programming.
Harnessing Artificial Intelligence for HIV: Breakthrough or Buzzword?
AVAC Infographics for AIDS 2026
For those presenting at AIDS 2026, AVAC’s latest infographics on the research and development pipeline, prevention options, and the impact of US funding cuts can be accessed here. We hope these are useful for presentations and discussions at the conference and beyond.
We constantly update these graphics, so check back for updates. The latest version of the deck will be available here.
AVAC Infographics for HIV Vaccine Awareness Day
For HIV Vaccine Awareness Day, AVAC’s latest infographics — covering preventive vaccines, bNAbs, the HIV prevention research pipeline, and the impact of US funding cuts — are available as easy-to-use slides.
AVAC Infographics for INTEREST 2026
For those presenting at INTEREST (as well as anyone interested in tracking the field), AVAC’s latest infographics on HIV R&D and the delivery pipeline, the current landscape of prevention options are available in an easy-to-use slide format—including lenacapavir for HIV PrEP (LEN) volume commitments, and the impact of US funding cuts with new data from PEPFAR. We hope these are useful for presentations and discussions at the conference and beyond.
We constantly update these graphics, so check back for updates. The latest version of the deck will be available here.
Opportunities, Controversies & Cruel Ironies
What's New & Next in HIV Prevention
View the slides from AVAC Executive Director Mitchell Warren plenary presentation at SYNChronicity 2026.
AVAC Infographics for CROI 2026
Going to CROI? AVAC’s up-to-date infographics — on the research & development pipeline, prevention options, and the impact of US funding cuts — are available here for use in conference presentations. We constantly update these graphics, so check back for updates. The latest version of the deck will be available here.
HIV Prevention R&D at Risk
Tracking the Impact of US Funding Cuts
The US presidential administration is actively working to dismantle HIV research and demolish the architecture of global health. The entire HIV response — from basic research and clinical development to policy, programs, and global access to life-saving treatment and prevention — is now under attack, and the world runs the risk of reversing the strides made to end HIV.
AVAC has put together this report, highlighting the impact of US cuts on the pipeline of HIV prevention research and development. AVAC will continue to track these cuts and their impact, to amplify the damage they will cause, and to fight for their reversal.
HIV Research on Pause
Impacts of US government cuts on HIV R&D
This presentation, delivered by AVAC’s Executive Director, Mitchell Warren at IAS 2025, shares a sobering picture of the sweeping changes to science, global health and particularly, HIV R&D since January 20, 2025. It outlines the impact of foreign aid cuts, NIH grant terminations, and policy shifts and shares a vision for the future.
Designing for the Future
Community perspectives for HIV prevention trials
Presented by AVAC’s Regional Program Manager for Research Engagement Grace Kumwenda at IAS 2025, this presentation summarizes community demands that future HIV prevention trials be ethical, acceptable, inclusive, feasible, and efficient.
Advocates’ Guide to Lenacapavir
Trial results and steps toward ensuring access
This wide-ranging slide deck gives a complete overview of lenacapavir — showing the overall prevention product pipeline, describes lenacapavir, compares it to other options, discusses the trials testing the product, next steps, and links to advocacy resources.